<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375284</url>
  </required_header>
  <id_info>
    <org_study_id>248.616</org_study_id>
    <nct_id>NCT00375284</nct_id>
  </id_info>
  <brief_title>A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS</brief_title>
  <official_title>A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (MirapexÂ®) in Patients With Idiopathic Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial is a 6-week, double-blind, randomized, active and placebo-controlled&#xD;
      parallel-group study with a primary objective of comparison of starting doses of pramipexole&#xD;
      fixed-dose (0.25 mg daily) and pramipexole titrated-dose (0.125 mg qd for 1 week, then 0.25&#xD;
      mg qd for the remaining 5 weeks) with placebo to evaluate efficacy and safety in treating RLS&#xD;
      symptoms in patients diagnosed with idiopathic RLS.&#xD;
&#xD;
      The secondary objectives of this study will be to assess the onset of action of symptomatic&#xD;
      relief of RLS for pramipexole with daily assessment of PGI and modified IRLS during two&#xD;
      intervals of the first 2 weeks (Days 2, 3 and 4 and Days 9, 10, and 11) and assessment of&#xD;
      IRLS, PGI and CGI-I at Weeks 1, 2, 4 and 6 (CGI-I additionally on Day 3).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>The co-primary endpoints are: Assessment of clinical response of treatment measured by the change from baseline in total IRLS score and CGI-I responder rate (at least much improved) after 6 weeks, 2 weeks and 1 week.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of action on Day 3 as measured by the CGI-I responder rate Onset of action as measured by PGI and modified IRLS score Clinical Global Impression of improvement Patient Global Impression IRLS as a responder rate VAS score for pain in limbs</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">404</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent consistent with ICH-GCP and local IRB/IEC requirements&#xD;
             obtained prior to any study procedures being performed and the ability and willingness&#xD;
             to comply with study treatment regimen and to attend study assessments.&#xD;
&#xD;
          2. Male or female out-patients 18 to 80 years of age.&#xD;
&#xD;
          3. Diagnosis of idiopathic RLS according to the clinical RLS criteria revised by the&#xD;
             IRLSSG in collaboration with the U.S.A. National Institutes of Health [P03-03355]. All&#xD;
             four criteria must be present to fulfil the diagnosis of RLS:&#xD;
&#xD;
             - An urge to move the legs, usually accompanied or caused by uncomfortable and&#xD;
             unpleasant sensations in the legs. (Sometimes the urge to move is present without the&#xD;
             uncomfortable sensations and sometimes the arms or other body parts are involved in&#xD;
             addition to the legs).&#xD;
&#xD;
             The urge to move or unpleasant sensations begin or worsen during periods of rest or&#xD;
             inactivity such as lying or sitting.&#xD;
&#xD;
               -  The urge to move or unpleasant sensations are partially or totally relieved by&#xD;
                  movement, such as walking or stretching, at least as long as the activity&#xD;
                  continues.&#xD;
&#xD;
               -  The urge to move or unpleasant sensations are worse in the evening or night than&#xD;
                  during the day or only occur in the evening or night. (When symptoms are very&#xD;
                  severe, the worsening at night may not be noticeable but must have been&#xD;
                  previously present).&#xD;
&#xD;
          4. RLS symptoms present at least 2 to 3 days per week during the last 3 months.&#xD;
&#xD;
          5. IRLS rating scale score &gt;15 at baseline (Visit 2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child-bearing potential (i.e., premenopausal women, or postmenopausal women&#xD;
             less than 6 months after last menses) who do not use during the clinical trial an&#xD;
             adequate method of contraception such as: double barrier protection (e.g., diaphragm&#xD;
             or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or&#xD;
             subcutaneous), or partners surgical sterilization.&#xD;
&#xD;
          2. Any women of child-bearing potential not having negative pregnancy test at screening.&#xD;
&#xD;
          3. Breastfeeding women.&#xD;
&#xD;
          4. Concomitant or previous pharmacologic therapy for RLS as follows:&#xD;
&#xD;
               -  Any intake of dopamine agonists within 14 days prior to baseline (Visit 2).&#xD;
&#xD;
               -  Any intake of L-dopa within 14 days prior to baseline (Visit 2).&#xD;
&#xD;
               -  Any intake of L-dopa prior to baseline visit, if augmentation in RLS symptoms was&#xD;
                  observed.&#xD;
&#xD;
               -  Unsuccessful prior treatment with non-ergot dopamine agonists (e.g., pramipexole,&#xD;
                  ropinirole).&#xD;
&#xD;
          5. All treatment less than 14 days before baseline (Visit 2) or concomitant treatment&#xD;
             with medication or dietary supplements which could significantly influence RLS&#xD;
             symptoms, e.g., dopaminergic (other than levodopa and dopamine agonists) or&#xD;
             antidopaminergic drugs, non-selective MAO inhibitors, sympathomimetics, neuroleptics,&#xD;
             antidepressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine,&#xD;
             ferrous salts, magnesium, folic acid, vitamin B12, antihistaminics, lithium,&#xD;
             metoclopramide.&#xD;
&#xD;
          6. Withdrawal symptoms of any medication must not be present at baseline (Visit 2).&#xD;
&#xD;
          7. Previous pramipexole non-responders in other indications than RLS.&#xD;
&#xD;
          8. Patients with known hypersensitivity to pramipexole or any other component of the&#xD;
             investigational product or placebo tablets.&#xD;
&#xD;
          9. Confirmed diagnosis of diabetes mellitus requiring insulin therapy.&#xD;
&#xD;
         10. Any of the following lab results at screening:&#xD;
&#xD;
               -  Patients with any clinically significant abnormalities in laboratory parameters&#xD;
                  at screening at the investigators discretion.&#xD;
&#xD;
               -  Haemoglobin (Hb) below lower limit of normal (LLN).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.616.065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wallingford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wellesley Hills</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clarks Summit</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rockwall</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.616.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.616_U08-3876.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.616_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

